 Connection
David Lynch to Treatment Outcome
This is a "connection" page, showing publications David Lynch has written about Treatment Outcome.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
0.399 |
|
|
|
-
Lynch DR, Hauser L, McCormick A, Wells M, Dong YN, McCormack S, Schadt K, Perlman S, Subramony SH, Mathews KD, Brocht A, Ball J, Perdok R, Grahn A, Vescio T, Sherman JW, Farmer JM. Randomized, double-blind, placebo-controlled study of interferon-? 1b in Friedreich Ataxia. Ann Clin Transl Neurol. 2019 03; 6(3):546-553.
Score: 0.057
-
Lynch DR, Farmer J, Hauser L, Blair IA, Wang QQ, Mesaros C, Snyder N, Boesch S, Chin M, Delatycki MB, Giunti P, Goldsberry A, Hoyle C, McBride MG, Nachbauer W, O'Grady M, Perlman S, Subramony SH, Wilmot GR, Zesiewicz T, Meyer C. Safety, pharmacodynamics, and potential benefit of omaveloxolone in Friedreich ataxia. Ann Clin Transl Neurol. 2019 01; 6(1):15-26.
Score: 0.056
-
Meier T, Perlman SL, Rummey C, Coppard NJ, Lynch DR. Assessment of neurological efficacy of idebenone in pediatric patients with Friedreich's ataxia: data from a 6-month controlled study followed by a 12-month open-label extension study. J Neurol. 2012 Feb; 259(2):284-91.
Score: 0.034
-
Lee H, Jin GY, Han YM, Chung GH, Lee YC, Kwon KS, Lynch D. Comparison of survival rate in primary non-small-cell lung cancer among elderly patients treated with radiofrequency ablation, surgery, or chemotherapy. Cardiovasc Intervent Radiol. 2012 Apr; 35(2):343-50.
Score: 0.033
-
Kim JS, Tanaka N, Newell JD, Degroote MA, Fulton K, Huitt G, Lynch DA. Nontuberculous mycobacterial infection: CT scan findings, genotype, and treatment responsiveness. Chest. 2005 Dec; 128(6):3863-9.
Score: 0.023
-
Mattos WLLD, Khalil N, Spencer LG, Bonella F, Folz RJ, Rolf JD, Mogulkoc N, Lancaster LH, Jenkins RG, Lynch DA, Noble PW, Maher TM, Cottin V, Senger S, Horan GS, Greenberg S, Popmihajlov Z. Phase 2, Double-Blind, Placebo-controlled Trial of a c-Jun N-Terminal Kinase Inhibitor in Idiopathic Pulmonary Fibrosis. Am J Respir Crit Care Med. 2024 Aug 15; 210(4):435-443.
Score: 0.021
-
O'Brien EM, Neiswinter N, Lin KY, Lynch D, Baldwin K, Profeta V, Flynn JM, Muhly WT. Perioperative management and outcomes for posterior spinal fusion in patients with Friedreich ataxia: A single-center, retrospective study. Paediatr Anaesth. 2024 07; 34(7):654-661.
Score: 0.020
-
Miller JE, Oh E, Khatiwada A, Humphries SM, Wilson A, Vladar EK, Lynch DA, Taylor-Cousar JL, Beswick DM. Two-Year Impact of Highly Effective Modulator Therapy on Olfactory Dysfunction. Laryngoscope. 2024 Jun; 134(6):2492-2494.
Score: 0.020
-
Beswick DM, Khatiwada A, Miller JE, Humphries SM, Wilson A, Vladar EK, Lynch DA, Taylor-Cousar JL. Impact of highly effective modulator therapy on chronic rhinosinusitis and health status: 2-year follow-up. J Cyst Fibros. 2024 Mar; 23(2):214-218.
Score: 0.020
-
Fern?ndez P?rez ER, Crooks JL, Lynch DA, Humphries SM, Koelsch TL, Swigris JJ, Solomon JJ, Mohning MP, Groshong SD, Fier K. Pirfenidone in fibrotic hypersensitivity pneumonitis: a double-blind, randomised clinical trial of efficacy and safety. Thorax. 2023 11; 78(11):1097-1104.
Score: 0.019
-
Solomon JJ, Danoff SK, Woodhead FA, Hurwitz S, Maurer R, Glaspole I, Dellaripa PF, Gooptu B, Vassallo R, Cox PG, Flaherty KR, Adamali HI, Gibbons MA, Troy L, Forrest IA, Lasky JA, Spencer LG, Golden J, Scholand MB, Chaudhuri N, Perrella MA, Lynch DA, Chambers DC, Kolb M, Spino C, Raghu G, Goldberg HJ, Rosas IO. Safety, tolerability, and efficacy of pirfenidone in patients with rheumatoid arthritis-associated interstitial lung disease: a randomised, double-blind, placebo-controlled, phase 2 study. Lancet Respir Med. 2023 01; 11(1):87-96.
Score: 0.018
-
Saperstein AM, Lynch DA, Qian M, Medalia A. How does awareness of cognitive impairment impact motivation and treatment outcomes during cognitive remediation for schizophrenia? Schizophr Res. 2020 04; 218:70-75.
Score: 0.015
-
Marchini L, Recker E, Hartshorn J, Cowen H, Lynch D, Drake D, Blanchette DR, Dawson DV, Kanellis M, Caplan D. Iowa nursing facility oral hygiene (INFOH) intervention: A clinical and microbiological pilot randomized trial. Spec Care Dentist. 2018 Nov; 38(6):345-355.
Score: 0.014
-
Yagihashi K, Huckleberry J, Colby TV, Tazelaar HD, Zach J, Sundaram B, Pipavath S, Schwarz MI, Lynch DA. Radiologic-pathologic discordance in biopsy-proven usual interstitial pneumonia. Eur Respir J. 2016 Apr; 47(4):1189-97.
Score: 0.012
-
Andrade J, Schwarz M, Collard HR, Gentry-Bumpass T, Colby T, Lynch D, Kaner RJ. The Idiopathic Pulmonary Fibrosis Clinical Research Network (IPFnet): diagnostic and adjudication processes. Chest. 2015 Oct; 148(4):1034-1042.
Score: 0.011
-
Hoffman EA, Lynch DA, Barr RG, van Beek EJ, Parraga G. Pulmonary CT and MRI phenotypes that help explain chronic pulmonary obstruction disease pathophysiology and outcomes. J Magn Reson Imaging. 2016 Mar; 43(3):544-57.
Score: 0.011
-
Kim HJ, Brown MS, Elashoff R, Li G, Gjertson DW, Lynch DA, Strollo DC, Kleerup E, Chong D, Shah SK, Ahmad S, Abtin F, Tashkin DP, Goldin JG. Quantitative texture-based assessment of one-year changes in fibrotic reticular patterns on HRCT in scleroderma lung disease treated with oral cyclophosphamide. Eur Radiol. 2011 Dec; 21(12):2455-65.
Score: 0.008
-
Goldin J, Elashoff R, Kim HJ, Yan X, Lynch D, Strollo D, Roth MD, Clements P, Furst DE, Khanna D, Vasunilashorn S, Li G, Tashkin DP. Treatment of scleroderma-interstitial lung disease with cyclophosphamide is associated with less progressive fibrosis on serial thoracic high-resolution CT scan than placebo: findings from the scleroderma lung study. Chest. 2009 Nov; 136(5):1333-1340.
Score: 0.007
|
Connection Strength
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
|